nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—EPHX2—metabolic syndrome X	0.742	1	CbGaD
Regorafenib—PDGFRA—penis—metabolic syndrome X	0.00538	0.056	CbGeAlD
Regorafenib—RET—autonomic nervous system—metabolic syndrome X	0.00532	0.0554	CbGeAlD
Regorafenib—Sorafenib—EPHX2—metabolic syndrome X	0.00496	0.834	CrCbGaD
Regorafenib—FLT4—endothelium—metabolic syndrome X	0.00289	0.0301	CbGeAlD
Regorafenib—TEK—artery—metabolic syndrome X	0.00275	0.0286	CbGeAlD
Regorafenib—FLT4—blood vessel—metabolic syndrome X	0.00266	0.0277	CbGeAlD
Regorafenib—FLT1—artery—metabolic syndrome X	0.00266	0.0277	CbGeAlD
Regorafenib—TEK—endothelium—metabolic syndrome X	0.00232	0.0242	CbGeAlD
Regorafenib—KDR—artery—metabolic syndrome X	0.00225	0.0234	CbGeAlD
Regorafenib—FLT1—endothelium—metabolic syndrome X	0.00224	0.0234	CbGeAlD
Regorafenib—EPHA2—blood vessel—metabolic syndrome X	0.00219	0.0229	CbGeAlD
Regorafenib—TEK—blood vessel—metabolic syndrome X	0.00214	0.0223	CbGeAlD
Regorafenib—FLT1—blood vessel—metabolic syndrome X	0.00207	0.0216	CbGeAlD
Regorafenib—DDR2—cardiovascular system—metabolic syndrome X	0.00195	0.0203	CbGeAlD
Regorafenib—KDR—endothelium—metabolic syndrome X	0.0019	0.0198	CbGeAlD
Regorafenib—KDR—blood vessel—metabolic syndrome X	0.00175	0.0182	CbGeAlD
Regorafenib—DDR2—adipose tissue—metabolic syndrome X	0.00172	0.0179	CbGeAlD
Regorafenib—KIT—endothelium—metabolic syndrome X	0.00168	0.0175	CbGeAlD
Regorafenib—MAPK11—adipose tissue—metabolic syndrome X	0.00163	0.017	CbGeAlD
Regorafenib—KIT—blood vessel—metabolic syndrome X	0.00155	0.0162	CbGeAlD
Regorafenib—PDGFRB—blood vessel—metabolic syndrome X	0.00151	0.0158	CbGeAlD
Regorafenib—FRK—liver—metabolic syndrome X	0.00134	0.014	CbGeAlD
Regorafenib—BRAF—adipose tissue—metabolic syndrome X	0.00122	0.0127	CbGeAlD
Regorafenib—DDR2—liver—metabolic syndrome X	0.00121	0.0126	CbGeAlD
Regorafenib—FLT4—cardiovascular system—metabolic syndrome X	0.00119	0.0124	CbGeAlD
Regorafenib—UGT1A9—kidney—metabolic syndrome X	0.00118	0.0123	CbGeAlD
Regorafenib—EPHX2—adipose tissue—metabolic syndrome X	0.00116	0.0121	CbGeAlD
Regorafenib—FLT4—adipose tissue—metabolic syndrome X	0.00105	0.0109	CbGeAlD
Regorafenib—FGFR1—adipose tissue—metabolic syndrome X	0.00103	0.0108	CbGeAlD
Regorafenib—RET—kidney—metabolic syndrome X	0.00103	0.0107	CbGeAlD
Regorafenib—FGFR2—cardiovascular system—metabolic syndrome X	0.000996	0.0104	CbGeAlD
Regorafenib—Sorafenib—HTR2C—metabolic syndrome X	0.000985	0.166	CrCbGaD
Regorafenib—EPHA2—cardiovascular system—metabolic syndrome X	0.000979	0.0102	CbGeAlD
Regorafenib—FGFR2—kidney—metabolic syndrome X	0.000975	0.0102	CbGeAlD
Regorafenib—TEK—cardiovascular system—metabolic syndrome X	0.000955	0.00995	CbGeAlD
Regorafenib—TEK—kidney—metabolic syndrome X	0.000934	0.00974	CbGeAlD
Regorafenib—FLT1—cardiovascular system—metabolic syndrome X	0.000923	0.00962	CbGeAlD
Regorafenib—RAF1—cardiovascular system—metabolic syndrome X	0.000918	0.00957	CbGeAlD
Regorafenib—FLT1—kidney—metabolic syndrome X	0.000903	0.00941	CbGeAlD
Regorafenib—RAF1—kidney—metabolic syndrome X	0.000898	0.00936	CbGeAlD
Regorafenib—FGFR2—adipose tissue—metabolic syndrome X	0.000878	0.00915	CbGeAlD
Regorafenib—PDGFRA—cardiovascular system—metabolic syndrome X	0.000865	0.00902	CbGeAlD
Regorafenib—EPHA2—adipose tissue—metabolic syndrome X	0.000863	0.009	CbGeAlD
Regorafenib—BRAF—liver—metabolic syndrome X	0.000852	0.00888	CbGeAlD
Regorafenib—TEK—adipose tissue—metabolic syndrome X	0.000842	0.00878	CbGeAlD
Regorafenib—EPHX2—liver—metabolic syndrome X	0.000814	0.00849	CbGeAlD
Regorafenib—FLT1—adipose tissue—metabolic syndrome X	0.000814	0.00848	CbGeAlD
Regorafenib—RAF1—adipose tissue—metabolic syndrome X	0.00081	0.00843	CbGeAlD
Regorafenib—UGT1A1—kidney—metabolic syndrome X	0.000808	0.00842	CbGeAlD
Regorafenib—KDR—cardiovascular system—metabolic syndrome X	0.000781	0.00813	CbGeAlD
Regorafenib—KDR—kidney—metabolic syndrome X	0.000764	0.00796	CbGeAlD
Regorafenib—PDGFRA—adipose tissue—metabolic syndrome X	0.000763	0.00795	CbGeAlD
Regorafenib—UGT1A9—liver—metabolic syndrome X	0.000745	0.00776	CbGeAlD
Regorafenib—FLT4—liver—metabolic syndrome X	0.000734	0.00765	CbGeAlD
Regorafenib—FGFR1—liver—metabolic syndrome X	0.000725	0.00755	CbGeAlD
Regorafenib—KIT—cardiovascular system—metabolic syndrome X	0.000692	0.00721	CbGeAlD
Regorafenib—KDR—adipose tissue—metabolic syndrome X	0.000688	0.00717	CbGeAlD
Regorafenib—KIT—kidney—metabolic syndrome X	0.000677	0.00705	CbGeAlD
Regorafenib—PDGFRB—cardiovascular system—metabolic syndrome X	0.000676	0.00704	CbGeAlD
Regorafenib—PDGFRB—kidney—metabolic syndrome X	0.000661	0.00689	CbGeAlD
Regorafenib—FGFR2—liver—metabolic syndrome X	0.000616	0.00642	CbGeAlD
Regorafenib—KIT—adipose tissue—metabolic syndrome X	0.00061	0.00636	CbGeAlD
Regorafenib—EPHA2—liver—metabolic syndrome X	0.000605	0.00631	CbGeAlD
Regorafenib—ABL1—cardiovascular system—metabolic syndrome X	0.000602	0.00627	CbGeAlD
Regorafenib—PDGFRB—adipose tissue—metabolic syndrome X	0.000596	0.00621	CbGeAlD
Regorafenib—TEK—liver—metabolic syndrome X	0.000591	0.00615	CbGeAlD
Regorafenib—ABL1—kidney—metabolic syndrome X	0.000589	0.00614	CbGeAlD
Regorafenib—FLT1—liver—metabolic syndrome X	0.000571	0.00595	CbGeAlD
Regorafenib—RAF1—liver—metabolic syndrome X	0.000568	0.00592	CbGeAlD
Regorafenib—PDGFRA—liver—metabolic syndrome X	0.000535	0.00558	CbGeAlD
Regorafenib—ABL1—adipose tissue—metabolic syndrome X	0.000531	0.00553	CbGeAlD
Regorafenib—UGT1A1—liver—metabolic syndrome X	0.00051	0.00532	CbGeAlD
Regorafenib—KDR—liver—metabolic syndrome X	0.000483	0.00503	CbGeAlD
Regorafenib—KIT—liver—metabolic syndrome X	0.000428	0.00446	CbGeAlD
Regorafenib—ABCB1—blood vessel—metabolic syndrome X	0.00042	0.00437	CbGeAlD
Regorafenib—PDGFRB—liver—metabolic syndrome X	0.000418	0.00435	CbGeAlD
Regorafenib—CYP2C8—kidney—metabolic syndrome X	0.000382	0.00398	CbGeAlD
Regorafenib—ABL1—liver—metabolic syndrome X	0.000372	0.00388	CbGeAlD
Regorafenib—CYP2B6—cardiovascular system—metabolic syndrome X	0.00035	0.00365	CbGeAlD
Regorafenib—CYP2C9—cardiovascular system—metabolic syndrome X	0.000347	0.00361	CbGeAlD
Regorafenib—CYP2B6—kidney—metabolic syndrome X	0.000343	0.00357	CbGeAlD
Regorafenib—ABCG2—adipose tissue—metabolic syndrome X	0.000335	0.00349	CbGeAlD
Regorafenib—CYP2C19—liver—metabolic syndrome X	0.000277	0.00288	CbGeAlD
Regorafenib—CYP3A4—kidney—metabolic syndrome X	0.000259	0.0027	CbGeAlD
Regorafenib—CYP2C8—liver—metabolic syndrome X	0.000242	0.00252	CbGeAlD
Regorafenib—ABCG2—liver—metabolic syndrome X	0.000235	0.00245	CbGeAlD
Regorafenib—CYP2B6—liver—metabolic syndrome X	0.000217	0.00226	CbGeAlD
Regorafenib—CYP2C9—liver—metabolic syndrome X	0.000215	0.00224	CbGeAlD
Regorafenib—ABCB1—cardiovascular system—metabolic syndrome X	0.000187	0.00195	CbGeAlD
Regorafenib—ABCB1—kidney—metabolic syndrome X	0.000183	0.00191	CbGeAlD
Regorafenib—ABCB1—adipose tissue—metabolic syndrome X	0.000165	0.00172	CbGeAlD
Regorafenib—CYP3A4—liver—metabolic syndrome X	0.000164	0.0017	CbGeAlD
Regorafenib—ABCB1—liver—metabolic syndrome X	0.000116	0.00121	CbGeAlD
Regorafenib—RAF1—Hemostasis—AKT1—metabolic syndrome X	5.76e-06	3.7e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SREBF1—metabolic syndrome X	5.74e-06	3.69e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSD11B1—metabolic syndrome X	5.7e-06	3.66e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOS3—metabolic syndrome X	5.69e-06	3.66e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IRS1—metabolic syndrome X	5.67e-06	3.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—LEP—metabolic syndrome X	5.67e-06	3.64e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—metabolic syndrome X	5.67e-06	3.64e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—AKT1—metabolic syndrome X	5.67e-06	3.64e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	5.64e-06	3.63e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CETP—metabolic syndrome X	5.63e-06	3.62e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—metabolic syndrome X	5.62e-06	3.61e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SREBF1—metabolic syndrome X	5.6e-06	3.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOA1—metabolic syndrome X	5.6e-06	3.6e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOS3—metabolic syndrome X	5.59e-06	3.59e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HMGCR—metabolic syndrome X	5.59e-06	3.59e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GOT2—metabolic syndrome X	5.59e-06	3.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—AKT1—metabolic syndrome X	5.58e-06	3.59e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ABCA1—metabolic syndrome X	5.58e-06	3.59e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—SLC2A4—metabolic syndrome X	5.58e-06	3.59e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SERPINE1—metabolic syndrome X	5.55e-06	3.57e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—metabolic syndrome X	5.55e-06	3.57e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SERPINE1—metabolic syndrome X	5.54e-06	3.56e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—metabolic syndrome X	5.46e-06	3.51e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—metabolic syndrome X	5.46e-06	3.51e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HMGCR—metabolic syndrome X	5.45e-06	3.51e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GOT2—metabolic syndrome X	5.45e-06	3.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—INS—metabolic syndrome X	5.43e-06	3.49e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOB—metabolic syndrome X	5.41e-06	3.48e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GGT1—metabolic syndrome X	5.4e-06	3.47e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GOT1—metabolic syndrome X	5.4e-06	3.47e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—metabolic syndrome X	5.39e-06	3.47e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SCARB1—metabolic syndrome X	5.39e-06	3.47e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TGFB1—metabolic syndrome X	5.37e-06	3.45e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—metabolic syndrome X	5.34e-06	3.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL2—metabolic syndrome X	5.34e-06	3.44e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOS3—metabolic syndrome X	5.3e-06	3.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOS3—metabolic syndrome X	5.29e-06	3.4e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TGFB1—metabolic syndrome X	5.27e-06	3.39e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PLA2G4A—metabolic syndrome X	5.27e-06	3.39e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1—metabolic syndrome X	5.25e-06	3.38e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—metabolic syndrome X	5.25e-06	3.38e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SREBF1—metabolic syndrome X	5.24e-06	3.37e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—NOS3—metabolic syndrome X	5.22e-06	3.36e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—NOS3—metabolic syndrome X	5.22e-06	3.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—AKT1—metabolic syndrome X	5.18e-06	3.33e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—LPL—metabolic syndrome X	5.17e-06	3.32e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PPARG—metabolic syndrome X	5.15e-06	3.31e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GOT2—metabolic syndrome X	5.09e-06	3.27e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HMGCR—metabolic syndrome X	5.09e-06	3.27e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	5.08e-06	3.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IRS1—metabolic syndrome X	5.06e-06	3.25e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—INS—metabolic syndrome X	5.05e-06	3.25e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TGFB1—metabolic syndrome X	5.04e-06	3.24e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	5.04e-06	3.24e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TGFB1—metabolic syndrome X	5.01e-06	3.22e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TGFB1—metabolic syndrome X	4.99e-06	3.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SERPINE1—metabolic syndrome X	4.99e-06	3.21e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCA1—metabolic syndrome X	4.98e-06	3.2e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SLC2A4—metabolic syndrome X	4.98e-06	3.2e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—AKT1—metabolic syndrome X	4.98e-06	3.2e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—AKT1—metabolic syndrome X	4.98e-06	3.2e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	4.96e-06	3.19e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CD36—metabolic syndrome X	4.91e-06	3.16e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ABCA1—metabolic syndrome X	4.86e-06	3.12e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC2A4—metabolic syndrome X	4.86e-06	3.12e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	4.85e-06	3.12e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LPA—metabolic syndrome X	4.85e-06	3.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—INS—metabolic syndrome X	4.84e-06	3.11e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GGT1—metabolic syndrome X	4.82e-06	3.1e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GOT1—metabolic syndrome X	4.82e-06	3.1e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—metabolic syndrome X	4.77e-06	3.07e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—metabolic syndrome X	4.77e-06	3.07e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—metabolic syndrome X	4.77e-06	3.07e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TGFB1—metabolic syndrome X	4.76e-06	3.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOS3—metabolic syndrome X	4.76e-06	3.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—metabolic syndrome X	4.76e-06	3.06e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GGT1—metabolic syndrome X	4.71e-06	3.03e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GOT1—metabolic syndrome X	4.71e-06	3.03e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	4.69e-06	3.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1—metabolic syndrome X	4.68e-06	3.01e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	4.65e-06	2.99e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—metabolic syndrome X	4.63e-06	2.98e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—metabolic syndrome X	4.59e-06	2.95e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOB—metabolic syndrome X	4.58e-06	2.95e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARA—metabolic syndrome X	4.57e-06	2.94e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCA1—metabolic syndrome X	4.54e-06	2.92e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC2A4—metabolic syndrome X	4.54e-06	2.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TGFB1—metabolic syndrome X	4.5e-06	2.89e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PLA2G4A—metabolic syndrome X	4.46e-06	2.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SERPINE1—metabolic syndrome X	4.45e-06	2.86e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—NOS3—metabolic syndrome X	4.43e-06	2.85e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AGT—metabolic syndrome X	4.42e-06	2.84e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—AKT1—metabolic syndrome X	4.4e-06	2.83e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GGT1—metabolic syndrome X	4.4e-06	2.83e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GOT1—metabolic syndrome X	4.4e-06	2.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—metabolic syndrome X	4.38e-06	2.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—AKT1—metabolic syndrome X	4.38e-06	2.82e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—LPL—metabolic syndrome X	4.38e-06	2.81e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—metabolic syndrome X	4.37e-06	2.81e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—metabolic syndrome X	4.33e-06	2.79e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	4.32e-06	2.78e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—metabolic syndrome X	4.3e-06	2.77e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOA1—metabolic syndrome X	4.28e-06	2.75e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—metabolic syndrome X	4.25e-06	2.73e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CD36—metabolic syndrome X	4.16e-06	2.67e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFB1—metabolic syndrome X	4.1e-06	2.63e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOB—metabolic syndrome X	4.09e-06	2.63e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—metabolic syndrome X	4.09e-06	2.63e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—metabolic syndrome X	4.07e-06	2.62e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFB1—metabolic syndrome X	4.06e-06	2.61e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—metabolic syndrome X	4.05e-06	2.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—metabolic syndrome X	4.05e-06	2.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—metabolic syndrome X	4.04e-06	2.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—metabolic syndrome X	4.03e-06	2.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFB1—metabolic syndrome X	4.01e-06	2.58e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOB—metabolic syndrome X	3.99e-06	2.57e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PLA2G4A—metabolic syndrome X	3.98e-06	2.56e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—metabolic syndrome X	3.97e-06	2.56e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—metabolic syndrome X	3.97e-06	2.55e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—LPL—metabolic syndrome X	3.91e-06	2.51e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PLA2G4A—metabolic syndrome X	3.88e-06	2.5e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	3.87e-06	2.49e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARA—metabolic syndrome X	3.87e-06	2.49e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCK—metabolic syndrome X	3.85e-06	2.47e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	3.85e-06	2.47e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	3.83e-06	2.46e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—LPL—metabolic syndrome X	3.81e-06	2.45e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—metabolic syndrome X	3.8e-06	2.44e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—metabolic syndrome X	3.77e-06	2.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—metabolic syndrome X	3.77e-06	2.43e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—metabolic syndrome X	3.77e-06	2.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—metabolic syndrome X	3.76e-06	2.42e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—metabolic syndrome X	3.76e-06	2.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—metabolic syndrome X	3.76e-06	2.42e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AGT—metabolic syndrome X	3.74e-06	2.41e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—metabolic syndrome X	3.73e-06	2.4e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOB—metabolic syndrome X	3.73e-06	2.4e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CETP—metabolic syndrome X	3.71e-06	2.39e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CD36—metabolic syndrome X	3.71e-06	2.39e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—INS—metabolic syndrome X	3.7e-06	2.38e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—metabolic syndrome X	3.69e-06	2.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—metabolic syndrome X	3.67e-06	2.36e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—metabolic syndrome X	3.67e-06	2.36e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—metabolic syndrome X	3.67e-06	2.36e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLA2G4A—metabolic syndrome X	3.63e-06	2.33e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOA1—metabolic syndrome X	3.63e-06	2.33e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CD36—metabolic syndrome X	3.62e-06	2.33e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—metabolic syndrome X	3.59e-06	2.31e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—metabolic syndrome X	3.58e-06	2.3e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—metabolic syndrome X	3.58e-06	2.3e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—LPL—metabolic syndrome X	3.56e-06	2.29e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	3.56e-06	2.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—metabolic syndrome X	3.51e-06	2.25e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—metabolic syndrome X	3.5e-06	2.25e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—metabolic syndrome X	3.5e-06	2.25e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—metabolic syndrome X	3.48e-06	2.24e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—metabolic syndrome X	3.47e-06	2.23e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	3.45e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARA—metabolic syndrome X	3.45e-06	2.22e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—metabolic syndrome X	3.39e-06	2.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—metabolic syndrome X	3.39e-06	2.18e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—metabolic syndrome X	3.39e-06	2.18e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CD36—metabolic syndrome X	3.38e-06	2.18e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARA—metabolic syndrome X	3.37e-06	2.17e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	3.36e-06	2.16e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	3.36e-06	2.16e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AGT—metabolic syndrome X	3.34e-06	2.15e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—metabolic syndrome X	3.31e-06	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—metabolic syndrome X	3.3e-06	2.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—metabolic syndrome X	3.3e-06	2.12e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—metabolic syndrome X	3.27e-06	2.11e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—metabolic syndrome X	3.27e-06	2.1e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AGT—metabolic syndrome X	3.26e-06	2.1e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—metabolic syndrome X	3.25e-06	2.09e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOA1—metabolic syndrome X	3.24e-06	2.08e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—metabolic syndrome X	3.2e-06	2.05e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—metabolic syndrome X	3.2e-06	2.05e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOA1—metabolic syndrome X	3.16e-06	2.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—metabolic syndrome X	3.15e-06	2.03e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARA—metabolic syndrome X	3.15e-06	2.02e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—INS—metabolic syndrome X	3.13e-06	2.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—metabolic syndrome X	3.13e-06	2.01e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—metabolic syndrome X	3.09e-06	1.98e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—metabolic syndrome X	3.06e-06	1.97e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AGT—metabolic syndrome X	3.05e-06	1.96e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—metabolic syndrome X	3.02e-06	1.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—metabolic syndrome X	3.02e-06	1.94e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	2.99e-06	1.92e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	2.99e-06	1.92e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—metabolic syndrome X	2.99e-06	1.92e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—metabolic syndrome X	2.97e-06	1.91e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOA1—metabolic syndrome X	2.95e-06	1.9e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	2.9e-06	1.86e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	2.9e-06	1.86e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—metabolic syndrome X	2.87e-06	1.85e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—metabolic syndrome X	2.85e-06	1.83e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—metabolic syndrome X	2.85e-06	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—metabolic syndrome X	2.83e-06	1.82e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—metabolic syndrome X	2.82e-06	1.81e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—metabolic syndrome X	2.81e-06	1.8e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—INS—metabolic syndrome X	2.8e-06	1.8e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—metabolic syndrome X	2.79e-06	1.79e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—metabolic syndrome X	2.78e-06	1.79e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—metabolic syndrome X	2.78e-06	1.79e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—metabolic syndrome X	2.75e-06	1.77e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—INS—metabolic syndrome X	2.73e-06	1.76e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—metabolic syndrome X	2.64e-06	1.7e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—metabolic syndrome X	2.63e-06	1.69e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—metabolic syndrome X	2.61e-06	1.68e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—metabolic syndrome X	2.6e-06	1.67e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—metabolic syndrome X	2.57e-06	1.65e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—metabolic syndrome X	2.56e-06	1.65e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—INS—metabolic syndrome X	2.55e-06	1.64e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—metabolic syndrome X	2.51e-06	1.62e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—metabolic syndrome X	2.5e-06	1.61e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOB—metabolic syndrome X	2.46e-06	1.58e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—metabolic syndrome X	2.45e-06	1.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—metabolic syndrome X	2.44e-06	1.57e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—metabolic syndrome X	2.43e-06	1.56e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—metabolic syndrome X	2.4e-06	1.54e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—metabolic syndrome X	2.4e-06	1.54e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—metabolic syndrome X	2.39e-06	1.54e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	2.39e-06	1.54e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—metabolic syndrome X	2.37e-06	1.53e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LPL—metabolic syndrome X	2.35e-06	1.51e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—metabolic syndrome X	2.34e-06	1.5e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—metabolic syndrome X	2.24e-06	1.44e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—metabolic syndrome X	2.24e-06	1.44e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD36—metabolic syndrome X	2.23e-06	1.44e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—metabolic syndrome X	2.19e-06	1.41e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—metabolic syndrome X	2.19e-06	1.41e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—metabolic syndrome X	2.12e-06	1.36e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	2.08e-06	1.33e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—metabolic syndrome X	2.05e-06	1.32e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—metabolic syndrome X	2.04e-06	1.31e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AGT—metabolic syndrome X	2.01e-06	1.29e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—metabolic syndrome X	1.97e-06	1.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—metabolic syndrome X	1.95e-06	1.25e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	1.95e-06	1.25e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	1.72e-06	1.1e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—INS—metabolic syndrome X	1.68e-06	1.08e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—metabolic syndrome X	1.54e-06	9.92e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—metabolic syndrome X	1.49e-06	9.59e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	1.48e-06	9.48e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	1.35e-06	8.67e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—metabolic syndrome X	1.26e-06	8.12e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—metabolic syndrome X	1.13e-06	7.25e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—metabolic syndrome X	1.1e-06	7.08e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—metabolic syndrome X	1.03e-06	6.61e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	6.78e-07	4.36e-06	CbGpPWpGaD
